On October 29, 2018, Berry Consultants proudly released the first in a series of short videos undertaken in our role as the Innovative Clinical Trials
In our first public National Heart, Lung, and Blood Institute (NHLBI) Innovative Clinical Trials Resource (ICTR) webinar, Berry Consultants' Kert Viele will review the value
Berry Consultants will again have a strong presence at this year’s ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop in Washington, D.C. on September 12-14, 2018. Team
Berry Consultants is once again a sponsor for this year's Joint Statistical Meetings (JSM) on July 28 – August 2 in Vancouver, British Columbia, Canada.
Hierarchical modeling is a powerful tool for making inferences about multiple groups in clinical trials, whether these groups are multiple indications or tumor types in
Berry Consultants is delighted to announce that FACTS 6.1 is ready for release! Building on FACTS 6, FACTS 6.1 adds two new Dose Escalation simulation
This week, we (Melanie Quintana, Roger Lewis, and myself) have an article in JAMA entitled “Bayesian Analysis : Use of Prior Information in Clinical Trials”
Platform trials can efficiently evaluate multiple treatments simultaneously and employ unique statistical analyses to define best therapies. They are a natural extension of Bayesian adaptive
Duke Clinical Research Institute is announcing a public meeting to disseminate and discuss the results of an NIH-funded project (known as ADAPT) to design a more
Berry Consultants is once again a sponsor and will have significant presence at this year's Joint Statistical Meetings (JSM) held on July 30 – August 4 in
© 2012-2023 All rights reserved - Berry Consultants